Here are the S-3 shelf registrations from Kodiak Sciences Inc (KOD) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow KOD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KOD filings page.
Kodiak Sciences Inc. filed an automatic shelf registration statement permitting the company or selling securityholders to offer common stock, preferred stock, debt securities, warrants and units from time to time, with specific terms set in prospectus supplements. The shelf places no aggregate limit on the number or amount of securities sold. Unless a supplement provides otherwise, Kodiak says it receives no proceeds from selling-securityholder sales; proceeds from company sales are intended for working capital, capital and operating expenditures, and general corporate purposes.
Kodiak’s late-stage retinal drug programs include Zenkuda, which has completed five Phase 3 studies; the company plans to submit a three-indication biologics license application for wet AMD, diabetic retinopathy and retinal vein occlusion in the fourth quarter of 2026. Tabirafusp-ted met vision and anatomical endpoints in Phase 3 DAYBREAK, with p-values of 0.0036 and less than 0.0001, respectively. For KSI-101, enrollment of the first 300-patient PEAK cohort is complete, with results on track for December 2026; enrollment of a 600-patient cohort across PEAK and PINNACLE is expected to finish in the fourth quarter of 2026, with data anticipated in the second quarter of 2027.